2017
DOI: 10.1371/journal.ppat.1006555
|View full text |Cite
|
Sign up to set email alerts
|

Cross-species conservation of episome maintenance provides a basis for in vivo investigation of Kaposi's sarcoma herpesvirus LANA

Abstract: Many pathogens, including Kaposi’s sarcoma herpesvirus (KSHV), lack tractable small animal models. KSHV persists as a multi-copy, nuclear episome in latently infected cells. KSHV latency-associated nuclear antigen (kLANA) binds viral terminal repeat (kTR) DNA to mediate episome persistence. Model pathogen murine gammaherpesvirus 68 (MHV68) mLANA acts analogously on mTR DNA. kLANA and mLANA differ substantially in size and kTR and mTR show little sequence conservation. Here, we find kLANA and mLANA act reciproc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

5
43
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
3
2
1

Relationship

2
4

Authors

Journals

citations
Cited by 20 publications
(48 citation statements)
references
References 73 publications
(87 reference statements)
5
43
0
Order By: Relevance
“…Under antibiotic selection, kLANA as well as mLANA-expressing cells (but not the parental ML12 cells) yielded hygromycin-resistant cultures, as was expected based on the previously reported ability of mLANA to support maintenance of episomes harboring KSHV terminal repeats [21]. We repeated our ChIP-qPCR analysis and additionally performed ChIP-Seq from the bulk-selected cultures at 33 days p.i., a similar late time point as in our previous MHV-68Δ50 or MHV-68Δ50-kLANA experiments.…”
Section: Resultsmentioning
confidence: 72%
See 3 more Smart Citations
“…Under antibiotic selection, kLANA as well as mLANA-expressing cells (but not the parental ML12 cells) yielded hygromycin-resistant cultures, as was expected based on the previously reported ability of mLANA to support maintenance of episomes harboring KSHV terminal repeats [21]. We repeated our ChIP-qPCR analysis and additionally performed ChIP-Seq from the bulk-selected cultures at 33 days p.i., a similar late time point as in our previous MHV-68Δ50 or MHV-68Δ50-kLANA experiments.…”
Section: Resultsmentioning
confidence: 72%
“…Given this, we wondered whether unique properties of kLANA that are not conserved in murine homolog (mLANA) may be required for rapid acquisition of H3K27-me3, potentially explaining the absence of this mark from MHV-68 episomes in singly or co-infected cells. Although KSHV and MHV-68 LANA preferentially bind to their cognate sites within the terminal repeats, a number of recent studies have suggested that they can also reciprocally support genome replication and maintenance [21-24]. We therefore sought to investigate the ability of a recombinant MHV-68 genome harboring a kLANA gene to attract H3K27-me3 marks.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…A chimera virus was developed (a mouse virus with a human viral gene) that inhibits human LANA protein (essential for maintaining infection and causing cancer) for treatment of human herpes virus infection and its associated cancers. Such strategies can also be applied for the generation of chimera viruses, which can be effective against some other lethal viruses such as the Epstein-Barr virus or the human papilloma virus responsible for cervical cancers (Habison et al, 2017). Very recently, a chimeric antigen receptor T (CAR-T) cell has been developed for the treatment of relapsed or refractory acute lymphoblastic leukemia.…”
Section: Chimeric Enterovirusmentioning
confidence: 99%